Mogrify raises $3.7 million USD seed funding to accelerate its mission
to transform cell therapy via direct cellular conversion
• Darrin M Disley, PhD, DSc, OBE, appointed as CEO
• New investment from Ahren Innovation Capital, 24Haymarket and Dr Disley
• Mogrify’s technology enables the conversion of any mature cell type into any other mature cell type
without going through a pluripotent stem cell- or progenitor cell-state
• Promises to address the unmet market need for cell types that exhibit safety, efficacy and scalable
manufacturing profiles suitable for development as lifesaving cell therapies
• Funding will support rapid acceleration of research, commercial and corporate operations
• Plan to raise a significant Series A round to capture a share of a $30 billion USD market opportunity
Cambridge, UK, 20th February 2019: Cell Mogrify Ltd (Mogrify), a UK company aiming to transform the
future development of cell therapies, today announced a second close on its seed funding, bringing the
total raised to $3.7 million USD, and the appointment of Darrin M Disley, PhD, DSc, OBE, as CEO. The
Company will use the funding to market novel IP and cell types generated using its proprietary direct
cellular conversion platform, which will power the development and manufacture of lifesaving cell
therapies across all therapeutic areas. The funding round was led by existing investor Ahren Innovation
Capital (Ahren), with 24Haymarket and Dr Disley also investing.
Alice Newcombe-Ellis, Founder and Managing Partner, Ahren Innovation Capital, said: “Mogrify’s
team has a strong track record of success, and their cutting-edge approach to direct cellular conversion has the potential to disrupt cell therapy, placing the Company in a unique position to address a large market opportunity. This is an exciting time for Mogrify and we are pleased to be supporting them.”
Notes to Editors
Prof Julian Gough Co-founder and CSO Mogrify
Dr Darrin M Disley, OBE CEO Mogrify
Alice Newcombe-Ellis Founder and Managing Partner Ahren Innovation Capital
For high-resolution and alternate images please contact Zyme Communications.
For further information please contact:
Darrin M Disley, PhD, OBE
Tel: +44 (0)7811 996 942
Mogrify has developed a proprietary direct cellular conversion technology, which makes it possible to transform (transmogrify) any mature human cell type into any other without going through a pluripotent stem cell- or progenitor cell-state.
Uniquely positioned to address a cell therapy market estimated to be $35 billion USD by 2023, Mogrify is commercializing its technology via IP licensing, product development, and drug development. Based in Cambridge, UK, the Company has raised $3.7 million USD seed funding from Ahren Innovation Capital, 24Haymarket and Dr Darrin M Disley, OBE.
With a philosophy espousing the importance of relationships and trust, Ahren provides long-term capital and support to exceptional founders and teams, empowering them to achieve the unimaginable
Ahren Innovation Capital was founded by Alice Newcombe-Ellis, together with Science Partners Sir Shankar Balasubramanian, Professor John Daugman, Professor Zoubin Ghahramani, Professor Steve Jackson, Professor Andy Parker, Sir Venki Ramakrishnan, Lord Martin Rees and Sir Gregory Winter.
About Darrin M Disley, PhD, DSc, OBE
Darrin is a scientist, entrepreneur, angel investor and enterprise champion who has raised $500 million USD business financing and closed $600 million USD in commercial deals.
For 11 years he was CEO of Horizon Discovery Group plc a company he led from seed funding to a $113 million USD IPO and a peak market capitalization of $550 million USD.
In recent years, he has been named UK Quoted Company Entrepreneur, UK Life Science Public Company, UK Iconic Male Entrepreneur, European Life Science Business Leader and Scrip Biotech and Pharma Executive of Year as well as one of the 100 game-changing disruptive UK entrepreneurs.
Darrin supports education, entrepreneurship and mentoring programs in the UK, via the Professor Christopher R Lowe Carpe Diem Enterprise Fund, and has backed over 40 start-up life science, technology and social enterprises.
Darrin is an Enterprise Fellow at the Department of Chemical Engineering and Biotechnology, University of Cambridge, Honorary Fellow of the Cambridge Judge Business School and Honorary Visiting Fellow at the School of Environmental and Life Science at the University of Salford.
He holds a BSc in Chemistry and a DSc (Honoris Causa) from the University of Salford and a PhD in Biotechnology from the University of Cambridge
In 2016 Darrin was conferred with a lifetime-held Queens Award for Enterprise Promotion and in 2018 was appointed Officer of the Order of the British Empire by Queen Elizabeth II for his services to business and enterprise in the healthcare sector.
About 24Haymarket www.24haymarket.com
24Haymarket is a premium deal-by-deal investment platform focused on high-growth businesses, investing up to £5 million in any company. 24Haymarket’s Investor Network includes several highly experienced private equity and venture capital investors, seasoned entrepreneurs and senior operators. We invest our own capital in direct alignment with entrepreneurs and typically seek Board representation to actively support their growth agenda. Since its inception in 2011, 24Haymarket has invested in more than 50 high-growth businesses.